| Advice Pool |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Estate Plan Trusts > Estate - How To Legally Avoid Taxes On Gifts And Inheritances - Part 2 |
|
Advice Pool - Estate - How To Legally Avoid Taxes On Gifts And Inheritances - Part 2
Last week I explained in theory how you can legally avoid paying taxes on gifts and inheritances. Avoiding taxes on gifts and inheritances is based on cost-basis. To help you apply this to your s According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ituation I want to share some real-life examples of how my clients use these principles to legally avoid paying taxes on gifts and inheritances. First, let’s briefly review cost-basis. When you ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in eceive an asset as a gift and sell it, you are responsible for paying capital gains tax. Capital gains tax is calculated using cost-basis. Cost-basis refers to how much money was invested in an a lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. set. When an asset is sold, the cost-basis is subtracted from the amount received to determine the gain or loss. Your amount of gain or loss then determines how much you will pay in capital gains here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe tax. In other words, you pay tax on the profit. Cost-basis becomes complicated when an appreciated asset is passed on to someone else, either through an outright gift or through an estate. If a d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro asset is passed on before the giver’s death, then the recipient assumes the same cost-basis as the giver. If the asset is passed on after the giver’s death, the recipient’s cost-basis is the mar ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc et value on the date used to calculate tax on the estate. This ‘stepped-up’ cost-basis can save tens of thousands of dollars in capital gains tax. A reader in St. Maries, Idaho was facing this v easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ery situation. A lady has owned some utility stock for decades, happily collecting the dividends. Now she’s getting older and wanted to give this stock to her son. Little did she know this would nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ave resulted in thousands of dollars in unnecessary taxes! If she had given these shares to her son, he would have a large capital gains tax bill when he sold the shares. The way the IRS sees it and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ his ‘profit’ wasn’t the gain since he received the gift; his profit was based on how much his mother originally paid for the shares. I explained that if the son inherited that stock after mom’s ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi eath, they would legally avoid paying 15% in taxes on decades’ worth of gains. They quickly agreed! The situation is far different for an elderly client of mine. He lives on a farm that has been ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a in his family for eight generations. He inherited the farm over the 70 years ago and, obviously, it has appreciated greatly. Since his estate will be over $1,500,000, his family could lose up to dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod 50% to estate taxes. Imagine -- his daughters could be forced to sell the farm after 8 generations so the tax could be paid! In this situation, it is better to pay capital gains tax of 15% then cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin state taxes of 50%. Plus, there isn’t any tax on the gains until the farm is sold. Since his daughters plan on passing it on to their children, the taxes can continue to be deferred for decades. tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen So he’s been carefully gifting the maximum amount he can to his daughters each year over the last ten years. We calculated that he will legally avoid $750,000 in estate taxes. Few of us have lar t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel e farms, but most retirees own their home. And many times, the home is the most highly appreciated asset of the entire estate. Unfortunately, as they get older many parents make the mistake of pu ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ting their child’s name on the deed to their house. This is an especially common practice for widows. What people don’t realize is that when they put their child’s name on the deed to their home y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products , the IRS considers that a gift. Therefore, the child has the same cost-basis as the parent. So when the child goes to sell the house later, he or she will face a hefty capital gains tax bill. If . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de the value of the estate is less than $1,500,000, there wouldn’t be any tax on the profit of the house if it was passed through the estate at death. So think twice before gifting someone an appre elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip iated asset. Remember that adding someone’s name to a bank or brokerage account is the same as a gift. With some simple planning you can legally avoid losing tens of thousands of dollars in taxes tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Why Should You Care About Your Web Site Colors? Home Owner Debt Consolidation Solutions
|